[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338950-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-338950-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","nsclc-from-tumorigenesis-immune-checkpoint-misuse-to-current-and-future-targeted-therapy","NSCLC - from tumorigenesis, immune checkpoint misuse to current and future targeted therapy","","Non-small cell lung cancer (NSCLC) is driven by multistep tumorigenesis involving diverse genetic and epigenetic alterations that contribute to high mortality. Clinical evidence also highlights dysregulated immune checkpoints as a key mechanism of NSCLC progression. The review links pathway abnormalities, oncogenic mutations, and checkpoint expression on tumor and immune cells to therapeutic response, and summarizes current targeted treatment knowledge. It emphasizes PD-1/PD-L1 and CTLA-4 antibody strategies, alongside emerging nanobody, probody, affibody, and DARPIN checkpoint modulators under active research and trials.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/nsclc-from-tumorigenesis-immune-checkpoint-misuse-to-current-and-future-targeted-therapy/338950/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/nsclc-from-tumorigenesis-immune-checkpoint-misuse-to-current-and-future-targeted-therapy/338950.png","ImageObject",300,407,{"name":42,"@type":43},"Patrick","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"What key mechanisms drive NSCLC progression discussed in the review?","Question",{"text":62,"@type":63},"The review describes multistep tumorigenesis supported by genetic and epigenetic alterations and, in parallel, immune checkpoint dysregulation that promotes immune evasion and cancer progression.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Which immune checkpoint interactions are emphasized for current and future therapies?",{"text":67,"@type":63},"It emphasizes antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as primary strategies for reactivating the immune system in NSCLC.",{"name":69,"@type":60,"acceptedAnswer":70},"What emerging therapeutic approaches targeting immune checkpoints are also covered?",{"text":71,"@type":63},"Besides antibodies, it discusses promising checkpoint-targeting platforms such as nanobodies, probodies, affibodies, and DARPINs, which are under active research or clinical trials.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},338950,1791355927,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":103,"preview_page_count":33,"preview_urls":144},549758146520,"https://ap-avatar.wpscdn.com/avatar/80002397d8c0411e94?_k=1775819394049821470","TYPE Review  \nPUBLISHED 07 February 2024  \nDOI 10.3389/fimmu.2024.1342086  \nOPEN ACCESS  \nEDITED BY  \nIoannis Vathiotis,  \nNational and Kapodistrian University of Athens, Greece  \nREVIEWED BY  \nGeorgii Vasiukov,  \nVanderbilt University, United States Maria Effrosyni Livanou,  \nNational and Kapodistrian University of Athens, Greece  \nKenji Morimoto,  \nKyoto Prefectural University of Medicine, Japan Afshan Fathima Nawas,  \nUniversity of Texas Southwestern Medical Center, United States  \nPrachi Jain,  \nDeaconess Henderson Hospital, United States  \n*CORRESPONDENCE Milan Raska  \n [milan.raska@upol.cz](milan.raska@upol.cz)[ ](milan.raska@upol.cz)Leona Raskova Kafkova  \n [leona.raskova@upol.cz](leona.raskova@upol.cz)  \nRECEIVED 21 November 2023  \nACCEPTED 17 January 2024  \nPUBLISHED 07 February 2024  \nCITATION  \nRaskova Kafkova L, Mierzwicka JM, Chakraborty P, Jakubec P, Fischer O, Skarda J, Maly P and Raska M (2024)  \nNSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy.  \nFront. Immunol. 15:1342086 .  \ndoi: 10.3389/fimmu.2024.1342086  \nCOPYRIGHT  \n© 2024 Raskova Kafkova, Mierzwicka, Chakraborty, Jakubec, Fischer, Skarda, Malyand Raska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nNSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy  \nLeona Raskova Kafkova 1,2*, Joanna M. Mierzwicka 3, Prosenjit Chakraborty 1, Petr Jakubec 4, Ondrej Fischer 4, Jozef Skarda 5,6, Petr Maly 3 and Milan Raska 1,2*  \n1 Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czechia, 2 Department of Immunology, University Hospital Olomouc, Olomouc, Czechia, 3 Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, Vestec, Czechia, 4 Department of Respiratory Diseases and Tuberculosis, University Hospital Olomouc, Olomouc, Czechia, 5 Institute of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czechia, 6 Department of Pathology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czechia  \nNon-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis process involving various genetic and epigenetic alterations, which essentially contribute to the high incidence of mortality among patients with NSCLC. Clinical observations revealed that NSCLC also co-opts a multifaceted immune checkpoint dysregulation as an important driving factor in NSCLC progression and development. For example, a deregulated PI3K/AKT/ mTOR pathway has been noticed in 50-70% of NSCLC cases, primarily modulated by mutations in key oncogenes such as ALK, EGFR, KRAS, and others. Additionally, genetic association studies containing patient-speciﬁc factors and local reimbursement criteria expose/reveal mutations in EGFR/ALK/ ROS/BRAF/KRAS/PD-L1 proteins to determine the suitability of available immunotherapy or tyrosine kinase inhibitor therapy. Thus, the expression of such checkpoints on tumors and immune cells is pivotal in understanding the therapeutic efﬁcacy and has been extensively studied for NSCLC treatments. Therefore, this review summarizes current knowledge in NSCLC tumorigenesis, focusing on its genetic and epigenetic intricacies, immune checkpoint dysregulation, and the evolving landscape of targeted therapies. In the context of current and future therapies, we emphasize the signiﬁcance of antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as the primary therapeutic strategy for immune system reactivation in NS","cbCaieqycUgetdam","https://ap.wps.com/l/cbCaieqycUgetdam","pdf",4572851,"English","# Introduction\n# Clinical aspects of NSCLC","[{\"question\":\"What key mechanisms drive NSCLC progression discussed in the review?\",\"answer\":\"The review describes multistep tumorigenesis supported by genetic and epigenetic alterations and, in parallel, immune checkpoint dysregulation that promotes immune evasion and cancer progression.\"},{\"question\":\"Which immune checkpoint interactions are emphasized for current and future therapies?\",\"answer\":\"It emphasizes antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as primary strategies for reactivating the immune system in NSCLC.\"},{\"question\":\"What emerging therapeutic approaches targeting immune checkpoints are also covered?\",\"answer\":\"Besides antibodies, it discusses promising checkpoint-targeting platforms such as nanobodies, probodies, affibodies, and DARPINs, which are under active research or clinical trials.\"}]","NSCLC - from tumorigenesis, immune checkpoint misuse to current and future targeted therapy | PDF",1790026741,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c91f10113bc07f311f790cec2083b91.webp",983,1389,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/59862db9aae89c55b012536ada30a9cb.webp",982,1388,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/70d533bdf9fc237f1d30075a46cfe0e7.webp",981,1386,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fe7ddacfbba7f2d6795cf816ecd0d024.webp",980,1385]